Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Personalizing Direct Oral Anticoagulant Therapy for a Diverse Population: Role of Race, Kidney Function, Drug Interactions, and Pharmacogenetics

20 Jul 2022

Abstract excerpt

Oral anticoagulants (OACs) are commonly used to reduce the risk of venous thromboembolism and the risk of stroke in patients with atrial fibrillation. Endorsed by the American Heart Association, American College of Cardiology, and the European Society of Cardiology, direct oral anticoagulants (DOACs) have displaced warfarin as the OAC of choice for both conditions, due to improved safety profiles, fewer drug-drug...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Atrial Fibrillation Management and Outcomes
Share to Blood Pressure and Hypertension Studies
Share to Venous Thromboembolism Diagnosis and Management

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35857814
DOI: 10.1002/cpt.2714

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Personalizing Direct Oral Anticoagulant Therapy for a Diverse Population: Role of Race, Kidney Function, Drug Interactions, and PharmacogeneticsPMID 35857814Read ↗

Clinical Review of the Pharmacogenomics of Direct Oral Anticoagulants.Semantic proximity Read ↗

Being precise with anticoagulation to reduce adverse drug reactions: are we there yet?Semantic proximity Read ↗

Phenotype-directed clinically driven low-dose direct oral anticoagulant for atrial fibrillation.Semantic proximity Read ↗

PHARMACOGENOMICS OF NOVEL ORAL ANTICOAGULANTS (NOACs): CURRENT INSIGHTS AND FUTURE DIRECTIONSSemantic proximity Read ↗

Pharmacogenetics of Novel Oral Anticoagulants: A Review of Identified Gene Variants & Future PerspectivesSemantic proximity Read ↗

Pharmacogenetics of warfarin: challenges and opportunitiesSemantic proximity Read ↗

Role of pharmacogenomics in the management of traditional and novel oral anticoagulants.Semantic proximity Read ↗

Pharmacogenomics of Novel Direct Oral Anticoagulants: Newly Identified Genes and Genetic VariantsSemantic proximity Read ↗

Genotype-guided warfarin therapy: current status.Semantic proximity Read ↗

Warfarin Pharmacogenomics in Diverse Populations.Semantic proximity Read ↗

Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of WarfarinSemantic proximity Read ↗

A regulatory science perspective on warfarin therapy: a pharmacogenetic opportunity.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.